allogeneic donor-derived t-cells transduced with bivalent lentiviral vector (cd19/cd22-bbz) chimeric antigen receptor (car)
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 18, 2022 (NCT05507827)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05507827 | Phase 1 | Aug 18, 2022 | Orca Biosystems, Inc., Stanford University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Orca Biosystems, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1